Finanzen von Aethlon Medical Inc (AEMD)AEMDAethlon Medical Inc

Aethlon Medical Inc (AEMD) generates its revenue primarily from Aethlon, which accounts for 100.0% of total sales, equivalent to $13.12K. Understanding this concentration is critical for investors evaluating how AEMD navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Aethlon Medical Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -160.91%, provide a clear picture of how effectively AEMD converts its operational activities into shareholder value.

In the context of the broader market, AEMD competes directly with industry leaders such as BBLG and VBIO. With a market capitalization of $1.46M, it holds a significant position in the sector. When comparing efficiency, AEMD's gross margin of N/A stands against BBLG's N/A and VBIO's N/A. Such benchmarking helps identify whether Aethlon Medical Inc is trading at a premium or discount relative to its financial performance.

Aethlon Medical has consistently reported net losses, with the latest Q1 2026 loss narrowing to $1.55 million from $1.76 million the previous year. The EPS for Q1 2026 was -4.02, showing a significant loss per share, although it is an improvement from -42.42 in the previous year. The company has a current ratio of 5.42, indicating good short-term liquidity, but the overall financial health remains concerning due to ongoing losses.